The economic burden of advanced gastric cancer in Taiwan

Abstract

BackgroundGastric cancer is one of the leading causes of cancer-related deaths in both sexes worldwide, especially in Eastern Asia. This study aimed to estimate the economic burden of advanced gastric cancer (AGC) in Taiwan.MethodsThe costs of AGC in 2013 were estimated using resource use data from a chart review study (n = 122 with AGC) and national statistics. Annual per-patient costs, where patients’ follow-up periods were adjusted for, were estimated with 82 patients who had complete resource use data. The costs were composed of direct medical costs, direct non-medical costs (healthcare travel and caregiver costs), morbidity costs, and mortality costs. Relevant unit costs were retrieved mainly from literature and national statistics, and applied to the resource use data. A broad definition of morbidity and mortality costs was employed to value the productivity loss in patients with unpaid employment, economically inactive and unemployed as well as the life years after the age of retirement. Their narrow definitions were also used in sensitivity analyses, using age- and/or sex-specific employment rates. Forgone future earnings/productivity loss were discounted at 3%. Annual per-patient costs were projected to estimate the total costs of AGC at the national level with an estimated number of patients with AGC (N = 2611) in Taiwan in 2013.ResultsThe mean age of the 82 patients was 59.3 (SD: 11.9) years, and 67.1% were male. Per-patient costs were US$26,431 for direct medical costs, US$4669 for direct non-medical costs, US$5758 for morbidity costs, and US$145,990 for mortality costs (per death). These per-patient costs were projected to incur total AGC costs of US$423 million at the national-level. Mortality costs accounted for 77.3% of the total costs, followed by direct medical costs (16.3%), morbidity costs (3.6%), and direct non-medical costs (2.9%).ConclusionAGC was found to exert a significant economic burden in Taiwan, incurring US$423 million in 2013. This represents about 0.08% of the Taiwanese economy. Mortality costs appeared to be the single greatest contributor to the burden, followed by direct medical costs. Early detection and providing effective treatments will help to reduce its burden on patients, caregivers and society as a whole.A poster of this study was presented at the 2016 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco, CA, USA.

Economic burden of cancers in Taiwan: a direct and indirect cost estimate for 2007–2017

“…In one Taiwanese study on advanced gastric cancer, the indirect costs were estimated to be 342 million US$ at the national-level, approximately 77% of the total costs. 13 Our results also showed that the indirect costs accounted for the major proportion (over 50%) of the total costs for most cancers, except prostate cancer and female breast cancer, due to their decreased mortality rates and older age at death. Without considering the indirect costs, the risk of underestimating the total economic burden of cancer is high.…”

“…This approach may underestimate the economic burden of cancers and may make justification of the value of innovative oncology treatment difficult. Second, most existing studies were limited to one single type of cancer 10–12 or a certain stage of one single type of cancer, 13 which makes comprehensive comparisons between different cancers impossible. Third, very few studies 14 have compared the economic burdens of cancers with other diseases, such as cardiovascular disease.…”

Clinical Evaluation of CA72-4 for Screening Gastric Cancer in a Healthy Population: A Multicenter Retrospective Study

“…In Taiwan, GC is the seventh leading cause of cancer-related deaths [24]. The economic burden of advanced GC accounts for 0.08% of the Taiwanese medical expense [25]. Although endoscopic biopsy along with histopathological evaluation is the gold standard for diagnosing GC, its invasiveness and high expense precludes it as a routine screening method.…”

Economic Burden of Gastric Cancer: A Case of Iran

“…The incidence of gastric cancer is particularly high in East Asia, followed by Central and Eastern Europe, and South America. 4 Gastric cancer is one of the main causes of death due to cancer in the 21st century. It is anticipated that by 2030, gastric cancer will be one of the main causes of mortality in the world, and by 2050, there will be 2.5 million new cases and 1.9 million deaths.…”